JP2022545158A5 - - Google Patents

Info

Publication number
JP2022545158A5
JP2022545158A5 JP2022503825A JP2022503825A JP2022545158A5 JP 2022545158 A5 JP2022545158 A5 JP 2022545158A5 JP 2022503825 A JP2022503825 A JP 2022503825A JP 2022503825 A JP2022503825 A JP 2022503825A JP 2022545158 A5 JP2022545158 A5 JP 2022545158A5
Authority
JP
Japan
Prior art keywords
alkyl
independently selected
halo
alkoxy
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022503825A
Other languages
English (en)
Japanese (ja)
Other versions
JP7566870B2 (ja
JP2022545158A (ja
Filing date
Publication date
Priority claimed from PCT/GB2019/052359 external-priority patent/WO2021032936A1/en
Application filed filed Critical
Publication of JP2022545158A publication Critical patent/JP2022545158A/ja
Publication of JP2022545158A5 publication Critical patent/JP2022545158A5/ja
Application granted granted Critical
Publication of JP7566870B2 publication Critical patent/JP7566870B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022503825A 2019-08-21 2020-02-13 酵素阻害剤 Active JP7566870B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2019/052359 WO2021032936A1 (en) 2019-08-21 2019-08-21 Enzyme inhibitors
GBPCT/GB2019/052359 2019-08-21
PCT/GB2020/050332 WO2021032937A1 (en) 2019-08-21 2020-02-13 Enzyme inhibitors

Publications (3)

Publication Number Publication Date
JP2022545158A JP2022545158A (ja) 2022-10-26
JP2022545158A5 true JP2022545158A5 (cg-RX-API-DMAC10.html) 2023-02-20
JP7566870B2 JP7566870B2 (ja) 2024-10-15

Family

ID=67777359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022503825A Active JP7566870B2 (ja) 2019-08-21 2020-02-13 酵素阻害剤

Country Status (15)

Country Link
US (1) US20220363668A1 (cg-RX-API-DMAC10.html)
EP (1) EP4017587A1 (cg-RX-API-DMAC10.html)
JP (1) JP7566870B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220051207A (cg-RX-API-DMAC10.html)
CN (1) CN114269430A (cg-RX-API-DMAC10.html)
AR (1) AR118085A1 (cg-RX-API-DMAC10.html)
AU (1) AU2020333222A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022000936A2 (cg-RX-API-DMAC10.html)
CA (1) CA3147228A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022000266A2 (cg-RX-API-DMAC10.html)
IL (1) IL289783A (cg-RX-API-DMAC10.html)
MX (1) MX2022002069A (cg-RX-API-DMAC10.html)
PH (1) PH12022550078A1 (cg-RX-API-DMAC10.html)
TW (1) TW202115033A (cg-RX-API-DMAC10.html)
WO (2) WO2021032936A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
EP4017850A1 (en) * 2019-08-21 2022-06-29 Kalvista Pharmaceuticals Limited Enzyme inhibitors
WO2025153806A1 (en) * 2024-01-15 2025-07-24 Kalvista Pharmaceuticals Limited Methods for determining amidolytic activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
CN103415301A (zh) 2011-03-09 2013-11-27 德国杰特贝林生物制品有限公司 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
WO2015171527A1 (en) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
WO2017123518A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Aminotriazole immunomodulators for treating autoimmune diseases
CA3025810A1 (en) 2016-05-23 2017-11-30 Manish P. PONDA Aminoacylindazole immunomodulators for treatment of autoimmune diseases
US10875851B2 (en) 2016-11-18 2020-12-29 Merck Sharp & Dohme Corp. Factor XIIa inhibitors
WO2018093716A1 (en) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS
CN111670034A (zh) 2017-11-29 2020-09-15 洛克菲勒大学 用于治疗自身免疫性疾病的吡喃并吡唑类和吡唑并吡啶类免疫调节剂
EP4017850A1 (en) 2019-08-21 2022-06-29 Kalvista Pharmaceuticals Limited Enzyme inhibitors

Similar Documents

Publication Publication Date Title
JP2022545159A5 (cg-RX-API-DMAC10.html)
JP2021088610A5 (cg-RX-API-DMAC10.html)
JP2019526582A5 (cg-RX-API-DMAC10.html)
JP2025509281A5 (cg-RX-API-DMAC10.html)
US20210261524A1 (en) Therapeutic compounds and compositions
JP2021523887A (ja) XIIa因子インヒビター
JP2012530703A5 (cg-RX-API-DMAC10.html)
RU2012144332A (ru) Циклоалкил-замещенное производное имидазола
JP2022506110A5 (cg-RX-API-DMAC10.html)
JP2019081782A (ja) トロンビン阻害剤としてのハロゲノピラゾール
JP2022527075A5 (cg-RX-API-DMAC10.html)
JP2024524214A5 (cg-RX-API-DMAC10.html)
US20210253550A1 (en) Therapeutic compounds and compositions
US20190315711A1 (en) Therapeutic compounds and compositions
ES2205536T3 (es) Derivados de pirazina, su preparacion y medicamentos que los contienen.
Björkman et al. Pharmacokinetics of quinacrine after intrapleural instillation in rabbits and man
JPH05194524A (ja) 血栓症および血管痙攣症の治療に有用な7−オキサビシクロヘプチル置換複素環式アミドプロスタグランジン類縁体
JP2022541311A5 (cg-RX-API-DMAC10.html)
JP2015521183A5 (cg-RX-API-DMAC10.html)
JP2021512894A5 (cg-RX-API-DMAC10.html)
JP2023524996A5 (cg-RX-API-DMAC10.html)
KR20200118088A (ko) 치료 화합물 및 조성물
RU2813780C2 (ru) Терапевтические соединения и композиции
JP2023541655A (ja) 治療用化合物、組成物およびその使用方法
JP2023525527A5 (cg-RX-API-DMAC10.html)